{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T19:22:59Z","timestamp":1793733779809,"version":"4.6.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,7,11]],"date-time":"2018-07-11T00:00:00Z","timestamp":1531267200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,7,11]],"date-time":"2018-07-11T00:00:00Z","timestamp":1531267200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C2559\/A16569"],"award-info":[{"award-number":["C2559\/A16569"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C2559\/A16569"],"award-info":[{"award-number":["C2559\/A16569"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C2559\/A16569"],"award-info":[{"award-number":["C2559\/A16569"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Synthetic pyrrolobenzodiazepine (PBD) dimers, where two PBD monomers are linked through their aromatic A-ring phenolic C8-positions via a flexible propyldioxy tether, are highly efficient DNA minor groove cross-linking agents with potent cytotoxicity. PBD dimer SG3199 is the released warhead component of the antibody-drug conjugate (ADC) payload tesirine (SG3249), currently being evaluated in several ADC clinical trials. SG3199 was potently cytotoxic against a panel of human solid tumour and haematological cancer cell lines with a mean GI<jats:sub>50<\/jats:sub> of 151.5 pM. Cells defective in DNA repair protein ERCC1 or homologous recombination repair showed increased sensitivity to SG3199 and the drug was only moderately susceptible to multidrug resistance mechanisms. SG3199 was highly efficient at producing DNA interstrand cross-links in naked linear plasmid DNA and dose-dependent cross-linking was observed in cells. Cross-links formed rapidly in cells and persisted over 36\u2009hours. Following intravenous (iv) administration to rats SG3199 showed a very rapid clearance with a half life as short as 8\u2009minutes. These combined properties of cytotoxic potency, rapid formation and persistence of DNA interstrand cross-links and very short half-life contribute to the emerging success of SG3199 as a warhead in clinical stage ADCs.<\/jats:p>","DOI":"10.1038\/s41598-018-28533-4","type":"journal-article","created":{"date-parts":[[2018,7,5]],"date-time":"2018-07-05T12:07:49Z","timestamp":1530792469000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":124,"title":["Pre-clinical pharmacology and mechanism of action of SG3199, the pyrrolobenzodiazepine (PBD) dimer warhead component of antibody-drug conjugate (ADC) payload tesirine"],"prefix":"10.1038","volume":"8","author":[{"given":"John A.","family":"Hartley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Flynn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Bingham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Corbett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Halla","family":"Reinert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2936-0515","authenticated-orcid":false,"given":"Arnaud","family":"Tiberghien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke A.","family":"Masterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dyeison","family":"Antonow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Adams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sajidah","family":"Chowdhury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David G.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shenlan","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay","family":"Harper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carin E. G.","family":"Havenith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Zammarchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Chivers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick H.","family":"van Berkel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip W.","family":"Howard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,7,11]]},"reference":[{"key":"28533_CR1","doi-asserted-by":"publisher","first-page":"5791","DOI":"10.1021\/ja00952a050","volume":"87","author":"W Leimgruber","year":"1965","unstructured":"Leimgruber, W. et al. Isolation and characterization of anthramycin, a new antitumour antibiotic. J. Am Chem Soc. 87, 5791\u20133 (1965).","journal-title":"J. Am Chem Soc."},{"key":"28533_CR2","doi-asserted-by":"crossref","unstructured":"Thurston, D. E. Molecular Aspects of Anticancer Drug-DNA Interactions. Vol. 1 (eds Neidle, S. & Waring, M. J.) Ch. 3, 54\u201388 (Macmillan, 1993).","DOI":"10.1007\/978-1-349-12356-8_3"},{"key":"28533_CR3","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1021\/bi00354a009","volume":"25","author":"RP Hertzberg","year":"1986","unstructured":"Hertzberg, R. P. et al. DNA sequence specificity of the pyrrolo[2,1-c][1,4]benzodiazepine antitumour antibiotics. Methidiumpropyl-EDTA-iron(II) footprinting analysis of DNA binding sites for anthramycin and related drugs. Biochemistry 25, 1249\u201358 (1986).","journal-title":"Biochemistry"},{"key":"28533_CR4","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1021\/tx00005a002","volume":"1","author":"LH Hurley","year":"1988","unstructured":"Hurley, L. H. et al. Pyrrolo[1,4]benzodiazepine antitumour antibiotics: relationship of DNA alkylation and sequence specificity to the biological activity of natural and synthetic compounds. Chem Res Toxicol. 1, 258\u201368 (1988).","journal-title":"Chem Res Toxicol."},{"key":"28533_CR5","doi-asserted-by":"publisher","first-page":"4939","DOI":"10.1021\/ja00038a089","volume":"114","author":"DS Bose","year":"1992","unstructured":"Bose, D. S. et al. Rational design of a highly efficient irreversible DNA interstrand cross-linking agent based on the pyrrolobenzodiazepine ring system. J Am Chem Soc 114, 4939\u201341 (1992).","journal-title":"J Am Chem Soc"},{"key":"28533_CR6","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/bjc.1994.248","volume":"70","author":"M Smellie","year":"1994","unstructured":"Smellie, M., Kelland, L. R., Thurston, D. E., Souhami, R. L. & Hartley, J. A. Cellular pharmacology of novel C8-linked anthramycin-based sequence-selective DNA minor-groove cross-linking agents. Br J Cancer. 70, 48\u201353 (1994).","journal-title":"Br J Cancer."},{"key":"28533_CR7","doi-asserted-by":"publisher","first-page":"4529","DOI":"10.1021\/jm00052a012","volume":"37","author":"TC Jenkins","year":"1994","unstructured":"Jenkins, T. C., Hurley, L. H., Neidle, S. & Thurston, D. E. Structure of a covalent DNA minor groove adduct with a pyrrolobenzodiazepine dimer: evidence for sequence specific interstrand cross-linking. J Med Chem 37, 4529\u20134537 (1994).","journal-title":"J Med Chem"},{"key":"28533_CR8","doi-asserted-by":"publisher","first-page":"8232","DOI":"10.1021\/bi034313t","volume":"42","author":"M Smellie","year":"2003","unstructured":"Smellie, M. et al. Sequence selective recognition of duplex DNA through covalent interstrand crosslinking: kinetic and molecular modelling studies with pyrrolobenzodiazepine (PBD) dimers. Biochemistry 42, 8232\u20139 (2003).","journal-title":"Biochemistry"},{"key":"28533_CR9","doi-asserted-by":"publisher","first-page":"13756","DOI":"10.1021\/ja902986x","volume":"131","author":"KM Rahman","year":"2009","unstructured":"Rahman, K. M., Thompson, A. S., James, C. H., Narayanaswamy, M. & Thurston, D. E. The pyrrolobenzodiaepine dimer SJG-136 forms sequence-dependent intrastrand cross-links and monoalkylatedadducts in addition to interstrand cross-links. J Am Chem Soc 131, 13756\u201366 (2009).","journal-title":"J Am Chem Soc"},{"key":"28533_CR10","doi-asserted-by":"publisher","first-page":"6693","DOI":"10.1158\/0008-5472.CAN-03-2941","volume":"64","author":"JA Hartley","year":"2004","unstructured":"Hartley, J. A. et al. SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumour activity: Part 1: Cellular pharmacology, in vitro and initial in vivo antitumour activity. Cancer Res 64, 6693\u20139 (2004).","journal-title":"Cancer Res"},{"key":"28533_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s12917-015-0534-2","volume":"11","author":"M Mellinas-Gomez","year":"2015","unstructured":"Mellinas-Gomez, M. et al. Activity of the minor groove cross-linking agent SG2000 (SJG-136) against canine tumours. BMC Veterinary Research 11, 215 (2015).","journal-title":"BMC Veterinary Research"},{"key":"28533_CR12","doi-asserted-by":"publisher","first-page":"6700","DOI":"10.1158\/0008-5472.CAN-03-2942","volume":"64","author":"MC Alley","year":"2004","unstructured":"Alley, M. C. et al. SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumour activity: Part 2: Efficacy evaluations. Cancer Res 64, 6700\u20136 (2004).","journal-title":"Cancer Res"},{"key":"28533_CR13","doi-asserted-by":"publisher","first-page":"3794","DOI":"10.1158\/1078-0432.CCR-10-2056","volume":"17","author":"I Puzanov","year":"2011","unstructured":"Puzanov, I. et al. Phase I pharmacokinetic and pharmacodynamic study of SJG-136, a novel DNA sequence selective minor groove cross-linking agent, in advanced solid tumors. Clin Cancer Res. 17, 3794\u2013802 (2011).","journal-title":"Clin Cancer Res."},{"key":"28533_CR14","doi-asserted-by":"publisher","first-page":"2140","DOI":"10.1158\/1078-0432.CCR-08-1315","volume":"15","author":"D Hochhauser","year":"2009","unstructured":"Hochhauser, D. et al. Phase I study of sequence-selective minor groove DNA binding agent SJG-136 in patients with advanced solid tumors. Clinical Cancer Res 15, 2140\u20132147 (2009).","journal-title":"Clinical Cancer Res"},{"key":"28533_CR15","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1007\/s00280-009-1088-4","volume":"65","author":"YY Janjigian","year":"2010","unstructured":"Janjigian, Y. Y. et al. A phase I trial of SJG-136 (NSC694501) in advanced solid tumors. Cancer Chemother. Pharmacol. 65, 833\u20138 (2010).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"28533_CR16","doi-asserted-by":"publisher","first-page":"6849","DOI":"10.1158\/0008-5472.CAN-10-0790","volume":"70","author":"JA Hartley","year":"2010","unstructured":"Hartley, J. A. et al. SG2285, a novel C2-aryl-substituted pyrrolobenzodiazepine dimer pro-drug that cross-links DNA and exerts highly potent antitumour activity. Cancer Res 70, 6849\u201358 (2010).","journal-title":"Cancer Res"},{"key":"28533_CR17","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1007\/s10637-011-9647-z","volume":"30","author":"JA Hartley","year":"2012","unstructured":"Hartley, J. A. et al. DNA interstrand cross-linking and in vivo antitumour activity of the extended pyrrolo[2,1-c][1,4]benzodiazepine dimer SG2057. Investigational New Drugs 30, 950\u2013958 (2012).","journal-title":"Investigational New Drugs"},{"key":"28533_CR18","doi-asserted-by":"crossref","unstructured":"Tiberghien A.C. et al. Design and Synthesis of Tesirine, a Clinical Antibody-Drug Conjugate Pyrrolobenzodiazepine Dimer Payload. ACS Medicinal Chemistry Letters (2016).","DOI":"10.1021\/acsmedchemlett.6b00062"},{"key":"28533_CR19","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/S1470-2045(16)30565-4","volume":"18","author":"CM Rudin","year":"2017","unstructured":"Rudin, C. M. et al. Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study. Lancet Oncology 18, 42\u201351 (2017).","journal-title":"Lancet Oncology"},{"key":"28533_CR20","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.1158\/1535-7163.MCT-16-0233","volume":"15","author":"MJ Flynn","year":"2016","unstructured":"Flynn, M. J. et al. ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer-Containing Antibody-Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies. Mol Cancer Ther 15, 2709\u20132721 (2016).","journal-title":"Mol Cancer Ther"},{"key":"28533_CR21","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1182\/blood-2017-10-813493","volume":"131","author":"F Zammarchi","year":"2018","unstructured":"Zammarchi, F. et al. ADCT-401, a PBD dimer-containing antibody drug conjugate tageting CD19-expressing malignancies. Blood 131, 1094\u20131105 (2018).","journal-title":"Blood"},{"key":"28533_CR22","doi-asserted-by":"publisher","first-page":"4371","DOI":"10.1016\/S0040-4039(00)96512-2","volume":"28","author":"R Deziel","year":"1987","unstructured":"Deziel, R. Mild palladium (O)-catalyzed deprotection of allyl esters. A useful application in the synthesis of carbapenems and other B-lactam derivatives. Tetrahedron Letters 28, 4371\u20134372 (1987).","journal-title":"Tetrahedron Letters"},{"key":"28533_CR23","doi-asserted-by":"publisher","first-page":"3283","DOI":"10.1093\/nar\/gki639","volume":"33","author":"PH Clingen","year":"2005","unstructured":"Clingen, P. H. et al. The XPF-ERCC1 endonuclease and homologous recombination contribute to the repair of minor groove DNA interstrand crosslinks in mammalian cells produced by the pyrrolo[2,1-c][1,4]benzodiazepine dimer SJG-136. Nucleic Acids Res. 33, 3283\u201391 (2005).","journal-title":"Nucleic Acids Res."},{"key":"28533_CR24","doi-asserted-by":"crossref","unstructured":"Kiakos, K., Hartley, J. M. & Hartley, J. A. Drug-DNA Interaction Protocols, 2nd Edn. (ed. Fox, K.), Ch. 18, 283\u2013302 (Humana, 2010).","DOI":"10.1007\/978-1-60327-418-0_18"},{"key":"28533_CR25","doi-asserted-by":"crossref","unstructured":"Spanswick V. J., Hartley J. M. & Hartley J. A. Drug-DNA Interaction Protocols, 2nd Edn. (ed. Fox, K.), Ch. 17, 267\u2013282 (Humana, 2010).","DOI":"10.1007\/978-1-60327-418-0_17"},{"key":"28533_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2012.148","volume":"3","author":"K-S Chan","year":"2012","unstructured":"Chan, K.-S., Koh, C.-G. & Li, H.-Y. Mitosis-targeted anticancer therapies: where they stand. Cell Death and Disease. 3, e411 (2012).","journal-title":"Cell Death and Disease."},{"key":"28533_CR27","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1182\/blood-2013-03-491506","volume":"122","author":"MS Kung Sutherland","year":"2013","unstructured":"Kung Sutherland, M. S. et al. SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML. Blood. 122, 1455\u201363 (2013).","journal-title":"Blood."},{"key":"28533_CR28","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1186\/1471-2407-12-436","volume":"12","author":"VJ Spanswick","year":"2012","unstructured":"Spanswick, V. J. et al. Evidence for different mechanisms of \u2018unhooking\u2019 for melphalan and cisplatin-induced DNA interstrand cross-links in vitro and in clinical acquired resistant tumour samples. BMC Cancer 12, 436\u201346 (2012).","journal-title":"BMC Cancer"},{"key":"28533_CR29","doi-asserted-by":"publisher","first-page":"302ra136","DOI":"10.1126\/scitranslmed.aac9459","volume":"7","author":"LR Saunders","year":"2015","unstructured":"Saunders, L. R. et al. A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo. Sci Trans Med 7, 302ra136 (2015).","journal-title":"Sci Trans Med"},{"key":"28533_CR30","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1182\/blood.V100.1.224","volume":"100","author":"VJ Spanswick","year":"2002","unstructured":"Spanswick, V. J. et al. Repair of DNA interstrand crosslinks as a mechanism of clinical resistance to melphalan in multiple myeloma. Blood 100, 224\u2013229 (2002).","journal-title":"Blood"},{"key":"28533_CR31","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1038\/sj.bjc.6603973","volume":"97","author":"P Wynne","year":"2007","unstructured":"Wynne, P. et al. Enhanced repair of DNA interstrand crosslinking in ovarian cancer cells from patients following treatment with platinum-based chemotherapy. Br. J. Cancer 97, 927\u2013933 (2007).","journal-title":"Br. J. Cancer"},{"key":"28533_CR32","doi-asserted-by":"publisher","first-page":"86","DOI":"10.2307\/3577587","volume":"122","author":"PL Olive","year":"1990","unstructured":"Olive, P. L., Banath, J. P. & Durand, R. E. Heterogeneity in radiation-induced DNA damage and repair in tumour and normal cells measured using the \u201ccomet\u201d assay. Radiation Res. 122, 86\u201394 (1990).","journal-title":"Radiation Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-28533-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-28533-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-28533-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T07:24:25Z","timestamp":1671607465000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-28533-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,11]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["28533"],"URL":"https:\/\/doi.org\/10.1038\/s41598-018-28533-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,11]]},"assertion":[{"value":"10 January 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.A.H., A.T., L.A.M., L.A., S.Cho., D.G.W. and P.W.H. are employees of Spirogen\/Medimmune Limited. S.M. and J.H. are employees of MedImmune. P.H.v.B., F.Z., S.C.hi. and C.E.G.H. are employees of A.D.C. Therapeutics and P.H.v.B., J.A.H. and P.W.H. are also shareholders. The authors declare no non-financial competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"10479"}}